|
Andrew Parkinson is founder and CEO of XenoTech LLC. He is also adjunct professor of Pharmacology and Toxicology at the University of Kansas Medical Center. Dr. Parkinson received a B.Sc. degree in medical biochemistry from the University of Surrey, England, in 1977 and received a Ph.D. degree in biological chemistry from the University of Guelph, Canada, in 1981. After completing his postdoctoral training in drug metabolism at Hoffmann-La Roche, Dr. Parkinson joined the faculty at the University of Kansas Medical Center where he was Professor of Pharmacology and Toxicology and Associate Director of the Center of Environmental and Occupational Health until June 30, 1999. He founded XenoTech LLC in 1994. Dr. Parkinson is a member of the editorial board of several scientific journals and is an active member of several scientific societies. He has served on NIH study section and is a consultant to several pharmaceutical companies and the FDA. Dr. Parkinson s research focuses mainly on hepatic drug metabolism and toxicity, with a special emphasis on cytochrome P450 and human-based in vitro systems. | 